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Considerable work has linked hormone receptors, such as estrogen receptor-alpha (ER), 
with the pioneer factor FOXA1. Altered FOXA1 levels contribute to endocrine-
resistant breast cancer, where it maintains ER-chromatin interactions, even in contexts 
where cells are refractory to ER-targeted drugs. A recent study, controversially suggests 
that FOXA1 binding can be induced by hormonal pathways, including the Estrogen-
ER complex. We now show that the previously observed estrogen-induced FOXA1 
binding sites are not technically reproducible and instead, the vast majority (>99%) of 
FOXA1 binding events are unaffected by steroid activation. A small number (<1%) of 
FOXA1 binding sites appear to be induced by estrogen, but these are created from 
chromatin interactions between ER binding sites and adjacent FOXA1 binding sites 
and do not represent genuine new FOXA1-pioneering elements. FOXA1 is therefore 
not regulated by estrogen and remains a bone fide pioneer factor that is entirely 
upstream of the ER complex. 
Introduction 
Whilst the term ‘pioneer factor’ has been used recently for any transcription factor that 
can mediate binding of another transcription factor to chromatin, a bone fide pioneer 
can associate with condensed chromatin, independently of other factors, to initiate 
chromatin opening and creation of a cis-regulatory element (Zaret and Carroll, 2011). 
FOXA1 is the archetypal pioneer factor, capable of binding to compact chromatin 
independently of other proteins and creating a localized euchromatic environment 
(Cirillo et al., 2002; Cirillo et al., 1998). It can mediate Estrogen Receptor (ER) binding 
events in breast cancer cell lines (Carroll et al., 2005; Hurtado et al., 2011; Laganiere 
et al., 2005), it is required for growth of drug-resistant cancer models (Hurtado et al., 
2011), and it has been shown to directly contribute to endocrine resistance (Fu et al., 
2016).  
FOXA1 has been shown to be important for other nuclear receptors (NR), such as 
Androgen Receptor (AR) in prostate cancer (Lupien et al., 2008), where elevated levels 
can contribute to disease outcome (Jain et al., 2011; Robinson et al., 2014). A role for 
FOXA1 in Castrate-Resistant Prostate Cancer (CRPC) is exemplified by the fact that 
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models of CRPC, driven by AR splice variants, are still dependent on FOXA1 for cell 
growth (He et al., 2018; Jones et al., 2015).  
FOXA1 binding has been consistently implicated as an event that happens upstream of 
NR association with cis-regulatory elements and experimental data to date, show no 
change in FOXA1 binding when ER is modulated (Hurtado et al., 2011) and FOXA1 
chromatin interaction does not require ER when exogenously expressed (Serandour et 
al., 2011). The dependence on a single catalytic transcription factor for hormone 
receptor signalling represents an attractive therapeutic target (Jozwik and Carroll, 2012; 
Nakshatri and Badve, 2007). Importantly, an inhibitor targeting FOXA1 would 
circumvent many of the known mechanisms of resistance, including changes in NR 
fidelity, growth factor activation, changes in the occupancy of co-factors and additional 
mechanisms that alter the binding potential or ligand dependency of the NR. 
The above-mentioned paradigms have recently been challenged, with a study 
suggesting that FOXA1 binding can be influenced by steroid activation of the cognate 
NR (Swinstead et al., 2016). This suggests that FOXA1 binding potential can be partly 
dictated by hormones, including estrogen and glucocorticoids. This questions the 
concept of transcription factor hierarchies, where specialized transcription factors can 
function as biological pathway-determining catalysts. We have repeated the key 
genomic transcription factor mapping experiments that lead to the paradigm-
challenging conclusions. We find that the estrogen-induced FOXA1 binding sites, 
which were described before (Swinstead et al., 2016), result from a lack of robust 
replicates and are not observable when additional, technically similar, ChIP-seq 
biological replicates are conducted. Any altered FOXA1 binding sites represent a tiny 
fraction of the overall FOXA1 binding sites (less than 1%) that result from chromatin 
loops that occur between cis-regulatory elements at estrogen-regulated gene regions, 
creating shadow binding events that do not represent new cis-regulatory elements.  
Results 
By mapping FOXA1 binding using ChIP-seq in ER+ breast cancer cells, Swinstead et 
al conclude that FOXA1 binding could be substantially altered by hormonal steroid 
treatment. The primary conclusion that FOXA1 binding was hormonally regulated was 
based largely on the results from their ChIP-seq experiments. We downloaded their 
FOXA1 ChIP-seq data conducted in breast cancer cell lines, but could not reproduce 
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the binding numbers described in the publication, due to insufficient information about 
peak calling and how input DNA was integrated into the analyses. We used the peak 
co-ordinates described in Swinstead et al and compared read densities of their duplicate 
libraries mapped to those coordinates using both Principal Component Analysis (PCA) 
and hierarchical clustering. Their samples did not cluster by treatment condition when 
assessed using PCA and samples from the same treatment condition showed substantial 
variability (Figure 1A), suggesting that the replicate samples were not similar. This lack 
of consistency between duplicates is a potential source of false positive ‘differential’ 
binding sites. As expected, differential peak patterns showed little consistency between 
replicates (Figure 1B) implying that any differential binding sites might be due to 
technical variability between replicates. Given this replicate-to-replicate variability 
(even between samples of the same treatment conditions), the lack of any ChIP-qPCR 
validation and the significant implication of the conclusions, we sought to repeat the 
key ChIP-seq experiments to determine if FOXA1 binding was in fact modulated by 
hormonal stimulation, as claimed (Swinstead et al., 2016). 
 
We hormone deprived MCF-7 and ZR-75-1 breast cancer cells and treated with vehicle 
or estrogen for 45 minutes, a time point shown to result in maximal ER binding and 
enhancer activity (Shang et al., 2000). ER ChIP-qPCR was conducted at known binding 
loci (Figure S1, Table S1), in order to confirm the estrogen-response. We subsequently 
conducted FOXA1 ChIP-seq experiments using two different antibodies, in both cell 
line models with three biological replicates from independent passages. Importantly, 
these were collected from matched experiments used to confirm estrogen 
responsiveness (Figure S1). One of the antibodies used in our study was the same 
antibody (ab23738) used by Swinstead et al. Matched Input samples were included for 
each experiment. Peaks were called using MACS2 (Ross-Innes et al., 2012; Stark and 
Brown). In MCF-7 cells, this resulted in 64,823 FOXA1 peaks in vehicle-treated and 
62,000 peaks in estrogen-treated conditions using the same antibody as Swinstead et 
al., and 37,318 vehicle and 35,925 estrogen FOXA1 peaks with the second independent 
antibody ab5089 (Table S2). PCA analysis of our samples showed that the samples 
clustered tightly based on replicates (Figure 1C), providing confidence when 
comparing peaks (Figure 1D). The samples clustered based on the antibody used for 
ChIP-seq and showed minimal difference between vehicle or estrogen conditions. In 
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ZR-75-1 cells, the ab23738 antibody generated 70,602 FOXA1 peaks in vehicle 
conditions and 66,604 peaks in estrogen conditions. The second antibody (ab5089) 
generated 35,763 FOXA1 peaks in vehicle conditions and 31,361 peaks in estrogen 
conditions (Table S2). As such, estrogen treatment did not result in a global increase in 
FOXA1 binding events, with either antibody or in either cell line assessed.  
One possibility is that FOXA1 binding could be redistributed, resulting in similar 
binding numbers, but at different locations in the genome. We therefore performed 
DiffBind analyses (Ross-Innes et al., 2012) (Table S3) and observed no FOXA1 
redistribution. In MCF-7 cells, there were 14 estrogen-induced peaks with the ab23738 
antibody and 2 peaks enriched in vehicle conditions, representing 0.02% of all FOXA1 
peaks that are estrogen induced (Figure 2A and C). This is in contrast to the results 
obtained using the exact same antibody and cell line in the Swinstead study, attesting 
to the potential problems that result from lack of sufficient replicates. The biggest 
change observed in any of the ChIP-seq experiments we undertook was in MCF-7 cells 
using the ab5089 FOXA1 antibody (which was not used in the Swinstead study) (Figure 
2A-C), which revealed a total of 357 FOXA1 peaks enriched in estrogen conditions 
(representing less than 1% of all peaks called) and 5 peaks enriched in vehicle 
conditions (Figure 2B).  
To establish the degree of variability in this ChIP-seq experiment conducted with 
sufficient biological replicates, we purposely mixed up the samples from the ab23738 
antibody-based ChIP-seq in different combinations and subsequently called peaks. 
Following DiffBind analysis, we found between 121 and 180 peaks that were 
considered differential, even in samples that were randomly mixed up with the incorrect 
treatment samples, representing ~0.5% of all peaks. 
In the ZR-75-1 cell line, we observed 23 estrogen-enriched and 2 vehicle-enriched 
FOXA1 binding sites using the same FOXA1 antibody used by Swinstead et al., (Figure 
2D and F). This small number of estrogen-induced FOXA1 binding sites represents less 
than 0.03% of all peaks. When using the second FOXA1 antibody (ab5089) in ZR-75-
1 cells, we found 109 estrogen-induced FOXA1 binding sites (0.03% of total FOXA1 
binding sites) and 1 vehicle-enriched site (Figure 2E). 
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Our ChIP-seq data with two different FOXA1 antibodies, conducted in two independent 
cell line models, revealed that 0.02-1% of the FOXA1 binding sites were induced by 
estrogen. This is in contrast to Swinstead et al., which claim that there is an appreciable 
number of FOXA1 binding events that can be hormonally regulated. Importantly, the 
same antibody that was used in the Swinstead study revealed no significant changes in 
FOXA1 binding in either cell line model in our ChIP-seq analysis.  
The second FOXA1 antibody (ab5089) that we utilized, produced a small number of 
estrogen-induced FOXA1 binding sites (357 sites), although it is important to note that 
these differential binding events constitute less than 1% of total FOXA1 binding events 
in the ChIP-seq dataset. Only 28 common FOXA1 binding events were identified in 
both MCF-7 and ZR-75-1 cell lines, implying that these differential sites are not 
reproducible between different cancer models (Figure 2G). 
Further analysis of the estrogen-induced FOXA1 binding sites in MCF-7 and ZR-75-1 
revealed the Estrogen Responsive Element (EREs) motif (p=1x10-42), but no Forkhead 
motifs (Figure 2H), suggesting that FOXA1 is not directly interacting with the 
chromatin at these regions. Based on the motif analysis, we hypothesized that the small 
number of estrogen-induced FOXA1 binding sites might be indirect FOXA1 binding 
events, potentially mediated via chromatin loops connecting estrogen-induced genes 
and their enhancers.  
Given the wealth of genomic, transcriptomic and chromatin looping data in the MCF-
7 cell line model, we investigated the underlying properties of the 357 estrogen-induced 
FOXA1 binding sites. We utilized published RNA-seq data following estrogen-
treatment of MCF-7 cells (Figure 3A) and observed that the 357 estrogen-induced 
FOXA1 binding sites were significantly biased towards the most estrogen-regulated 
genes (Figure 3B) with almost all of the binding sites within cis-regulatory domains 
adjacent to ER target genes.  
It is well established that lineage specific genes tend to be regulated by clusters of 
transcription factor binding sites (Hnisz et al., 2013; Whyte et al., 2013). This is true 
for estrogen-regulated genes, where the classic estrogen-induced genes (i.e. those with 
the greatest estrogen response) are regulated by clusters of closely associated cis-
regulatory domains (Carroll et al., 2006). Several well-characterized ER target genes 
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are shown in Figure 3C as examples. As typified by the examples shown, there are 
FOXA1 and ER co-bound regions, but importantly, there are sites where one 
transcription factor binds but the other one does not.  The 357 estrogen-induced FOXA1 
binding sites are all adjacent to an independent ER binding event and other FOXA1 
binding sites (Figure 3D and 3E), indicating their presence in regions of enriched 
transcription factor binding.  
Following estrogen-mediated stimulation, physical associations between cis-regulatory 
elements occur (Fullwood et al., 2009; Pan et al., 2008) and we postulated that FOXA1 
could associate with adjacent ER binding sites through chromatin looping.  Due to the 
cross-linking in the ChIP-seq protocol, these indirect chromatin loops create FOXA1 
binding sites that are not direct cis-regulatory elements and therefore represent ‘shadow 
peaks’. At these regions, FOXA1 does not function as a pioneer factor and new 
regulatory elements are not created. Our hypothesis is that the small fraction (<1%) of 
FOXA1 binding events that appear to be induced by estrogen, are in fact simply indirect 
peaks mediated via ER at those genomic regions. To assess this possibility, we utilized 
the ChIA-PET data that provides an unbiased map of the ER-mediated chromatin 
interactions that occur, in the presence of estrogen, in MCF-7 cells (Fullwood et al., 
2009). Of the 357 estrogen induced FOXA1 peaks in MCF-7 cells, 89% of these were 
detected in experimentally identified ER ChIA-PET chromatin loops (Figure 4A). 
Examples of estrogen-induced FOXA1 binding sites existing within ChIA-PET 
chromatin loops, are shown in Figure 4B. This finding confirms that the limited number 
of estrogen-induced FOXA1 binding events are in fact created by clusters of cis-
regulatory elements brought into proximity during gene expression. Therefore, FOXA1 
is a bone fide pioneer factor that binds upstream of nuclear receptors and direct FOXA1-
chromatin binding is not influenced by steroid hormones. 
Discussion 
It is well established that many nuclear receptors and other transcription factors regulate 
genes from significant distances (Carroll et al., 2005) (Lin et al., 2007). However, 
additional factors are required for NR to work (Glass and Rosenfeld, 2000; Shang et 
al., 2000). Recent observations have revealed that cells containing mutations in ER 
(ESR1) can be enriched due to selective pressure imposed by specific ER targeted drugs 
(Merenbakh-Lamin et al., 2013) (Robinson et al., 2013) (Toy et al., 2013), resulting in 
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ligand-independent ER activity. As such, there is a significant interest in defining 
critical components of the ER complex that might constitute potential drug targets. One 
such protein is FOXA1, a pioneer factor, shown to facilitate chromatin ‘opening’ 
independently of additional proteins, enabling binding and activity of other 
transcription factors. Importantly, this includes ER in breast cancer and Androgen 
Receptor (AR) in prostate cancer. Whilst additional modes of nuclear receptor binding 
can occur, such as assisted loading, involving complexes of multiple ATP-dependent 
chromatin factors (Voss et al., 2011), an absolute dependence on a single functionally 
catalytic protein, such as FOXA1, holds promise for therapeutic exploitation.  
FOXA1 has been shown to be required for growth of resistant cancers (Hurtado et al., 
2011), it contributes to endocrine resistance (Fu et al., 2016), and importantly, it is 
essential for ER binding and activity, even in endocrine resistant contexts (Hurtado et 
al., 2011). This places FOXA1 as a key driver of resistance and reveals a vulnerability 
in the ER pathway, where absolute dependence on a single upstream pioneer factor, 
creates an opportunity for therapeutic intervention, potentially overcoming known 
mechanisms of resistance. Interest in FOXA1 as a therapeutic target for ER+ breast 
cancer (Jozwik and Carroll, 2012; Nakshatri and Badve, 2007, 2009) was compromised 
by recent claims that FOXA1 binding is estrogen regulated (Swinstead et al., 2016). 
The significance of this conclusion means that ER targeted agents should, in theory, 
show effectiveness in inhibiting FOXA1 binding and transcriptional potential, reducing 
the need for developing direct FOXA1 inhibitors. Our comprehensive analysis of 
FOXA1 binding following estrogen stimulation reveals no appreciable estrogen 
regulation of FOXA1 binding. Different antibodies and different ER+ breast cancer cell 
line models show that >99% of FOXA1 binding sites are impervious to hormonal 
context. The residual FOXA1 changes represent less than 1% of FOXA1 binding events 
and result from peaks formed within clusters of ER/FOXA1 binding sites at genes that 
are estrogen regulated. As such, these lack the hallmarks of genuine FOXA1 binding 
sites, they do not result in the creation of new regulatory elements and they do not result 
in new gene expression events. The lack of robust, reproducible FOXA1 binding sites 
confirms that FOXA1 binding is not estrogen regulated and functions upstream of ER 
activity. In support to this conclusion, previous experimental data showed that the 
breast cancer treatment, Fulvestrant (ICI 182780), an ER degrader, does not alter 
FOXA1 binding (Hurtado et al., 2011). 
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The major distinction in conclusions between the Swinstead et al work and the current 
dataset, result from technical differences that can be attributed to insufficient replicates 
in the previous study (Figure 1). A lack of biological and/or technical replicates are a 
source of problems in the reproducibility of ChIP-seq datasets, particularly when 
claiming treatment or condition-specific binding events. We conclude that recent 
claims of estrogen-mediated FOXA1 binding events are influenced, in large part, by a 
lack of independent biological ChIP-seq replicates and duplicate samples that show 
unacceptable variability between purportedly replicate samples (Figure 1A and 1B).  
Swinstead et al., identified similar steroid hormone changes in FOXA1 binding in two 
distinct systems, namely estrogen responsiveness and dexamethasone-activation of GR 
(Swinstead et al., 2016). Whilst we have only focused on the estrogen-treated 
conditions, it is reasonable to assume that the majority of dex-mediated changes in 
FOXA1 are also false positives that result from a lack of independent biological 
replicates. This is based on the fact that the experimental approach was comparable and 
the same degree of differential FOXA1 binding was observed in both hormonal 
systems. The conclusion that steroids could change FOXA1 binding was suggested in 
large part by ChIP-seq analyses. In addition to these assays, Swinstead et al, also 
assessed FOXA1 chromatin dwell time using an exogenous, tagged-FOXA1 based 
approach (Swinstead et al., 2016). Despite the caveat that exogenous FOXA1 alters 
levels and potentially the function of endogenous FOXA1 and the tagged protein might 
not faithfully recapitulate endogenous FOXA1, there was a minimal change in FOXA1 
dwell time comparing the presence or absence of estrogen, suggesting that this non-
ChIP-based method supports the conclusion that FOXA1 binding is not altered in an 
appreciable way by hormone status.  
Understanding what enables FOXA1 binding is of importance and recent suggestions 
that steroid hormones could function in this capacity to modulate FOXA1-DNA 
binding potential (Swinstead et al., 2016) present an attractive hypothesis. We show 
that the vast majority (>99%) of FOXA1 binding is not regulated by estrogen and the 
small fraction of altered FOXA1 binding events are created via chromatin interactions 
during the course of estrogen-receptor mediated gene expression. FOXA1 therefore 
exists entirely upstream of the nuclear receptor, its chromatin binding capacity is not 
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influenced by estrogen signalling and it remains a relevant and important drug target in 
hormone-dependent cancers. 
Author Contributions 
Experiments were designed by S-E.G and J.S.C and all work was conducted by S-E.G. 
All bioinformatic work was conducted by I.C. All authors wrote the paper. 
Acknowledgements 
The authors would like to thank the genomics core and the Bioinformatics Core at 
Cancer Research UK Cambridge Institute. We thank Dr. Sankari Nagarajan and Dr. 
Rasmus Siersbæk from CRUK Cambridge Institute, for critical reading of the 
manuscript. We thank Danya Cheeseman and Emily Archer Goode for help compiling 
information about the methods. We acknowledge the support of the University of 
Cambridge and Cancer Research UK. J.S.C is supported by an ERC Consolidator award 
(Project number 646876), CRUK funding and a Komen Scholarship. 
 
Conflict of interest 
Jason Carroll is the Founder and CSO of Azeria Therapeutics. 
Figure legends 
Figure 1: PCA analysis and unbiased clustering of the different ChIP-seq datasets. 
Read densities from aligned libraries of equal size of 20 million reads were measured 
on corresponding FOXA1 binding sites from Swinstead et al (GEO identifier: 
GSE72249). A. The peaks for all treatments were merged in a single set prior to the 
measurement for each study and obtained data was subjected to PCA. The PCA plots 
illustrate degree of similarity between the replicates. B. Hierarchical clustering of the 
Swinstead et al binding sites. For hierarchical clustering of the Swinstead et al binding 
sites, the yielded read densities were normalized using median absolute deviation and 
clustered in MATLAB framework using “ward” method with the linkage function. The 
duplicate samples from Swinstead et al, did not cluster based on treatment condition. 
C. PCA analysis of our FOXA1 ChIP-seq generated with two different FOXA1 
antibodies (ab23738 and ab5089). D. Hierarchical clustering of our FOXA1 binding 
sites, showing clustering based on replicates.  
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Figure 2: Analysis of FOXA1 ChIP-seq binding with two separate antibodies in 
response to estrogen treatment in MCF-7 and ZR-75-1 cells. ChIP-seq tag densities 
visualized at FOXA1-occupied genomic locations in control and estrogen-treated 
MCF-7 (A and C) and ZR-75-1 (D and F) cells, using antibodies ab23738 and ab5089. 
Zoomed heatmap show differential binding of FOXA1 specific to ab5089 in MCF-7 
cells (B) and ZR-75-1 (E), respectively; G. Overlap of estrogen-enriched FOXA1 
binding sites between MCF-7 and ZR-75-1 cells; H. Transcription factor motifs found 
overrepresented in the common and estrogen induced FOXA1 sites.  
Figure 3: Integration of the estrogen-enriched FOXA1 binding events with 
estrogen-mediated gene expression events. A. RNA-seq expression profile following 
short-term (3hr) estrogen treatment of MCF-7, shown as a dispersion plot. B. GSEA 
Pre-ranked test correlating estrogen-induced genes with the 357 estrogen-induced 
FOXA1 binding sites. C. Examples of sites co-bound by FOXA1 and ER, as well as 
sites unique to each of the two transcription factors. Proximity of estrogen-induced 
FOXA1 peaks and the closest ER (D) or FOXA1 (E) site. Heat map represents FOXA1-
gained sites in red. 
Figure 4: ER binding mediates indirect FOXA1 binding via chromatin looping at 
cis-regulatory elements. A. Correlation between ER-mediated chromatin interactions 
(ChIA-PET) and the 357 estrogen-induced FOXA1 binding sites (ab5089). The table 
shows the correlation values between ChIA-PET interactions and the 357 estrogen-
induced FOXA1 binding sites. B. Examples of ER and FOXA1 peaks at regions that 
are involved in chromatin loops, as detected by ChIA-PET. The images of the ChIA-
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EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell culture  
MCF-7 and ZR-75-1 cell lines were obtained from ATCC (Middlesex, UK) and 
represent female breast cancer cell line models. MCF-7 cells were cultured in 
Dulbecco’s Modified Eagle Medium DMEM (Gibco, Thermo Scientific, 
Leicestershire, UK, ref. 41966). ZR-75-1 cells were grown in RPMI-1640 medium 
(Gibco, Thermo Scientific, Leicestershire, UK, ref. 21875-034). Both media were 
supplemented with foetal bovine serum (FBS), 50 U/ml penicillin, 50 μg/ml 
streptomycin and 2 mM L-glutamine.   
MCF-7 and ZR-75-1 cells were seeded and treated either with ethanol or with 10nM 
Estrogen (Sigma) for 45 minutes previously described (Schmidt et al., 2009).  All cell 
lines were regularly genotyped to ensure they were the correct cell lines. 
METHOD DETAILS 
Chromatin Immunoprecipitation  
To validate the Estrogen induction, ER ChIP-qPCR was performed using the rabbit 
polyclonal sc-543 (Santa Cruz) antibody. FOXA1 ChIP-seq was performed using the 
goat polyclonal ab5089 (Abcam), and rabbit polyclonal ab23738 (Abcam) antibodies. 
Chromatin was prepared as previously described (Schmidt et al., 2009). DNA was 
isolated and purified using the phenol-chloroform-isoamyl DNA extraction method. 
ChIP-seq and the input libraries were prepared using the ThruPlex® DNA-seq kit 
(Rubicon Genomics, ref. R400407).   
Integration of RNA-seq and ChIP-seq data  
Genes located around +/- 50kb from the peak regions were selected. –log10 
transformed p-values from DESeq2 analyses of the RNA-Seq data were subsequently 
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used for ranking and weighting of genes. GSEAPreranked (18) analysis tool from Gene 
Set Enrichment Analysis (GSEA) software, version 2.2.3, was used for the evaluation 
of statistically significant genes. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
ChIP Sequencing Analysis 
ER ChIP-qPCR and FOXA1 ChIP-seq were performed in biological triplicates, using 
cells from independent passages. 
ChIP-seq reads were mapped to hg38 genome using bowtie2 2.2.6 (Langmead and 
Salzberg, 2012). Aligned reads with the mapping quality less than 5 were filtered out. 
The read alignments from three replicates were combined into a single library and peaks 
were called using MACS2 version 2.0.10.20131216 (Zhang et al., 2008) with 
sequences from MCF7 chromatin extracts as a background input control. The peaks 
yielded with MACS2 q value <= 1e-3 were selected for downstream analysis. MEME 
tool FIMO version 4.9.1 (Bailey et al., 2009) was used for searching all known TF 
motifs from JASPAR database (JASPAR CORE 2016 vertebrates) in the tag-enriched 
sequences. As a background control, peak size - matching sequences corresponding to 
known open chromatin regions in MCF7 cells were randomly selected from hg38. 
Motif frequency for both tag-enriched and control sequences calculated as sum of motif 
occurrences adjusted with MEM q-value. Motif enrichment analysis was performed by 
calculating odds of finding an overrepresented motif among MACS2-defined peaks by 
fitting Student's t-cumulative distribution to the ratios of motif frequencies between tag-
enriched and background sequences. Yielded p-values were further adjusted using 
Benjamini-Hochberg correction. 
For visualizing tag density and signal distribution, heatmaps were generated with the 
read coverage in a window of +/- 2.5 or 5 kb region flanking the tag midpoint using the 
bin size of 1/100 of the window length. Differential binding analysis (Diffbind) was 
performed as described previously (Stark and Brown). 
DATA AND SOFTWARE AVAILABILITY 
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All ChIP-seq data is deposited in GEO under the accession number: GSE112969. Data 
can be accessed using the password: gzmtegactlqtxwp 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 





Goat Anti-FOXA1 polyclonal antibody – ChIP grade  
  
Abcam Cat# ab5089, 
RRID; 
AB_304744 
Rabbit Anti-FOXA1 polyclonal antibody – ChIP grade  Abcam Cat# ab23738, 
RRID; 
AB_2104842 
Bacterial and Virus Strains  
Biological Samples 
Chemicals, Peptides, and Recombinant Proteins 
Dynabeads® Protein A  Invitrogen Cat#10001D 
Dynabeads® Protein G Invitrogen Cat#10003D 
Pierce™ 16% Formaldehyde (w/v), Methanol-free Thermo Scientific Cat# 28908 
β-Estradiol Sigma-Aldrich Cat# E8875 
Dulbecco’s Modified Eagle Medium (DMEM) GIBCO Cat# 41966029 
RPMI 1640 Medium  GIBCO Cat# 21875034 
Fetal Bovine Serum, qualified, heat inactivated GIBCO Cat# 16140071 
Fetal Bovine Serum, charcoal stripped GIBCO Cat# 12676029 
Penicillin-Streptomycin GIBCO Cat#15070063 
L-Glutamine (200 mM) GIBCO Cat# 25030081 
Trypsin-EDTA (0.5%), no phenol red GIBCO Cat# 15400054 
cOmplete EDTA-free Protease inhibitor cocktail Sigma-Aldrich Cat# 05056489 
001 
Phosphatase Inhibitor cocktail Thermo Scientific Cat#78427 
Critical Commercial Assays 
ThruPlex® DNA-seq kit Rubicon Genomics Cat# R400407  
Deposited Data 





Experimental Models: Cell Lines 








Experimental Models: Organisms/Strains 
Oligonucleotides 
Primer for ChIP Forward: ER3 negative site (5’- 
GCCACCAGCCTGCTTTCTGT-3’) 
This study  n/a 
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Primer for ChIP Reverse: ER3 negative site (5’- 
CGTGGATGGGTCCGAGAAAC-3’) 
This study  n/a 
Primer for ChIP Forward: XBP1 negative site (5’- 
ACCCTCCAAAATTCTTCTGC-3’)  
This study  n/a 
Primer for ChIP Reverse: XBP1 negative site (5’- 
ATGAGCATCTGAGAGCAAGC-3’) 
This study  n/a 
Primer for ChIP Forward: XBP1 target site (5’- 
ATACTTGGCAGCCTGTGACC-3’) 
This study  n/a 
Primer for ChIP Reverse: XBP1 target site (5’- 
GGTCCACAAAGCAGGAAAAA-3’) 
This study  n/a 
Primer for ChIP Forward: GREB1 target site (5’- 
GAAGGGCAGAGCTGATAACG-3’)  
This study  n/a 
Primer for ChIP Reverse: GREB1 target site (5’- 
GACCCAGTTGCCACACTTTT-3’)  
This study  n/a 
Primer for ChIP Forward: MYC target site (5’- 
GCTCTGGGCACACACATTGG-3’) 
This study  n/a 
Primer for ChIP Reverse: MYC target site (5’- 
GGCTCACCCTTGCTGATGCT-3’) 
This study  n/a 
Recombinant DNA 
Software and Algorithms 










MEME tool FIMO v4.9.1  
 

















GSEAPreranked (18) analysis tool Gene  
















DESeq2 Love et al., 2014 https://bioconduct
or.org/packages/re
lease/bioc/html/D
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Motif enriched in common sites: 
FOXA1   p=1e-32
Motif enriched in gained sites:












































































Overlap of estrogen-induced FOXA1 
















Upregulated genes vs 
FOXA1 gained sites  
Positively 
correlated 
Enrichment Score (ES) 1
Nominal p value <0.001















-5kb          0          5kb
Proximity of E2- induced FOXA1 peaks to 



















0            8kb0            2kb
C
Examples of sites co-bound by FOXA1 and 














FOXA1 ChIP-seq: E2 gained sites
RNA-seq: E2 upregulated genes
E2 induced genes: Ranking metric score
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Figure 3




































































1        
Correlation between ER-mediated chromatin interactions 
and E2- induced FOXA1 sites
ChIA-PET Results Summary
sample no. sites
no. of sites overlapped 
with FOXA1 gained 
peaks 
ER ChIA-PET Rep1 14393 319
ER ChIA-PET Rep2 
(technical rep) 14393 319
ER ChIA-PET Rep3 2710 200
ER ChIA-PET Rep4 6671 257
A
Figure 4




Figure S1: Related to Figure 1. Validation of estrogen activity in MCF-7 (A) and ZR-75-1 
(B) cells. ER ChIP-qPCR was conducted in biological triplicates and these samples were 
matched with the FOXA1 ChIP-seq used for the study. The data is related to the samples 
used in Figure 1. 
A BMCF-7- ER ChIP-qPCR ZR-75-1- ER ChIP-qPCR
Supplemental Figures and tables
Table S1: Related to data used in Supplemetary Figure 1 and Figure 1. Primer sets used 
for ER ChIP-qPCR. Two control regions and three previously validated ER target regions were 
included. 
Gene name Forward primer Reverse primer
ER3 negative site GCCACCAGCCTGCTTTCTGT CGTGGATGGGTCCGAGAAAC
XBP1 negative site ACCCTCCAAAATTCTTCTGC ATGAGCATCTGAGAGCAAGC
XBP1 target site ATACTTGGCAGCCTGTGACC GGTCCACAAAGCAGGAAAAA
GREB1 target site GAAGGGCAGAGCTGATAACG GACCCAGTTGCCACACTTTT
MYC target site GCTCTGGGCACACACATTGG GGCTCACCCTTGCTGATGCT
Table S2: Related to data in Figure 1. Total number of peaks called in each condition. 















Table S3: Related to Figure 2. Differential binding comparison between vehicle 
and estrogen treatment. 




ab23738 Estrogen vs Vehicle 14 2 72627
ab5089 Estrogen vs Vehicle 357 5 41948
ZR-75-1
ab23738 Estrogen vs Vehicle 23 2 76830
ab5089 Estrogen vs Vehicle 109 1 38205
